

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



LIFE HEALTHCARE GROUP LIMITED

蓮和醫療健康集團有限公司

(incorporated in the Cayman Islands with limited liability)

(Stock Code: 928)

CHANGE OF DIRECTORS AND CHANGE IN COMPOSITION OF BOARD COMMITTEES

The Board hereby announces that with effect from 21 October 2022:

- (1) Dr. Wang, Bruce Xianliang has been appointed as an independent non-executive Director, chairman of each of the Audit Committee and the Nomination Committee and a member of the Remuneration Committee;
- (2) Dr. Zhao, Shawn Xiaohong has been appointed as an independent non-executive Director, chairman of the Remuneration Committee and a member of the Audit Committee;
- (3) Mr. Liu Xinghua has been resigned as an independent non-executive Director, chairman of the Remuneration Committee and a member of the Audit Committee; and
- (4) Mr. Wang Yang has been resigned as an independent non-executive Director, chairman of each of the Audit Committee and the Nomination Committee and a member of the Remuneration Committee.

The board (the “**Board**”) of directors (“**Directors**”) of Life Healthcare Group Limited (the “**Company**”) announces the followings:

APPOINTMENT OF INDEPENDENT NON-EXECUTIVE DIRECTORS

Dr. Wang

The board is pleased to announce that Dr. Wang, Bruce Xianliang (“**Dr. Wang**”) has been appointed as an independent non-executive Director, chairman of each of the audit committee of the Company (“**Audit Committee**”) and the nomination committee of the Company (“**Nomination Committee**”) and a member of the remuneration committee of the Company (“**Remuneration Committee**”) with effect from 21 October 2022.

Dr. Wang, aged 61, previously served as senior deputy general manager, chief risk officer, chief operating officer successively of China Resources Capital Management Limited from June 2017 to April 2021. He was senior vice president and chief human resources officer of China Resources Beer (Holdings) Co., Limited (formerly known as China Resources Enterprises, Limited), a company listed on the Hong Kong Stock Exchange (stock code: 291), from January 2014 to May 2016. He was deputy human resources director of China Resources (Holdings) Co., Limited from August 2010 to December 2013. Before joining China Resources Group, Dr. Wang was principal solutions officer and M&A advisory services director of Mercer Consulting (China), general manager of Mercer Consulting North China, principal of Mercer Human Resources Consulting in New York. Prior to that he was a senior analyst at National Economic Research Associates (New York) and consultant at the World Bank in Washington DC.

Dr. Wang was appointed as non-executive director of GenesisCare from October 2017 to April 2021, director of Asia Food Growth Fund from November 2019 to April 2021, and director of China M&A Association from February 2004 to June 2008.

Dr. Wang holds a PhD in Economics from Northwestern University in the U.S. and an MS degree from the Massachusetts Institute of Technology.

Dr. Wang has not held (i) any other position in the Company and other members of the Group; (ii) any directorship in any other public companies the securities of which are listed on any securities market in Hong Kong or overseas in the last three years; and (iii) any other major appointments and professional qualifications.

As the date of this announcement, Dr. Wang has no relationships with any Directors, senior management, substantial or controlling shareholders of the Company (having the meaning ascribed to it in the Rules Governing the Listing of Securities on the Stock Exchange of Hong Kong Limited (the “**Listing Rules**”)) and does not have any interests in the securities of the Company within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) (“**SFO**”).

Under the letter of appointment entered into between Dr. Wang and the Company, Dr. Wang’s term of service is 2 years. His directorship in the Company is subject to rotation and re-election at annual general meetings of the Company in accordance with the articles of association of the Company. The remuneration of Dr. Wang is HK\$20,000 per month which is determined by the Board and the Remuneration Committee with reference to his experience, duties and responsibilities within the Company.

Dr. Wang confirmed that he has met the independence criteria set out in Rule 3.13 of the Listing Rules.

Save as disclosed above, there are no other matters relating to the appointment of Dr. Wang that need to be brought to the attention of shareholders of the Company (the “**Shareholders**”) and there is no other information that should be disclosed pursuant to Rule 13.51(2)(h) to (v) of the Listing Rules.

Dr. Zhao

The Board is pleased to announce Dr. Zhao, Shawn Xiaohong (“**Dr. Zhao**”) has been appointed as an independent non-executive director, chairman of the Remuneration Committee and a member of the Audit Committee with effect from 21 October 2022.

Dr. Zhao, aged 64, is deputy director of Technology Transfer Office at Hong Kong University from July 2020. He has many years of successful domestic and Asian business development, technology transfer, and product development experience in various industries including batteries/battery materials, separation/filtration, and composite materials. Dr. Zhao was the program director of the Office of Corporate Relations at MIT from June 2015 to July 2020. Before joining MIT OCR, he was v.p. of Commercial Development and director of Product Development at Porous Power Technologies/Ahlstrom Group in Shanghai, founder of MatCo Company of Westborough, MA, general manager and CTO at PolyOne Co. in China, project leader at Hollingsworth and Vose Co. in Walpole, MA, material research manager at PGI in Charlotte, NC and as a research scientist at International Paper Co. in Boston.

Dr. Zhao is the deputy managing director of Versitech Limited and a board member of LSCM R&D Centre. He has many other affiliations including as executive director of the Board of 128 CUTE, as adjunct professor of Lanzhou Jiaotong University, as a member of the American Chemical Society, as a member of the Electrochemical Society, and as a member of the Material Research Society.

Dr. Zhao holds a PhD in Physical Chemistry from MIT.

Dr. Zhao has not held (i) any other position in the Company and other members of the Group; (ii) any directorship in any other public companies the securities of which are listed on any securities market in Hong Kong or overseas in the last three years; and (iii) any other major appointments and professional qualifications.

As the date of this announcement, Dr. Zhao has no relationships with any Directors, senior management, substantial or controlling shareholders of the Company (having the meaning ascribed to it in the Listing Rules) and does not have any interests in the securities of the Company within the meaning of Part XV of the SFO.

Under the letter of appointment entered into between Dr. Zhao and the Company, Dr. Zhao’s term of service is 2 years. His directorship in the Company is subject to rotation and re-election at annual general meetings of the Company in accordance with the articles of association of the Company. The remuneration of Dr. Zhao is HK\$20,000 per month which is determined by the Board and the Remuneration Committee with reference to his experience, duties and responsibilities within the Company.

Dr. Zhao confirmed that he has met the independence criteria set out in Rule 3.13 of the Listing Rules.

Save as disclosed above, there are no other matters relating to the appointment of Dr. Zhao that need to be brought to the attention of the Shareholders and there is no other information that should be disclosed pursuant to Rule 13.51(2)(h) to (v) of the Listing Rules.

The Board would like to express a warm welcome to Dr. Wang and Dr. Zhao for joining the Board.

RESIGNATION OF INDEPENDENT NON-EXECUTIVE DIRECTORS

Mr. Liu Xinghua (“**Mr. Liu**”) has resigned as an independent non-executive Director, chairman of the Remuneration Committee and a member of the Audit Committee, with effect from 21 October 2022 in order to focus his time on other assignments. Mr. Liu has confirmed that he has no disagreement with the Board and there are no matters relating to his resignation which need to be brought to the attention of the Shareholders or The Stock Exchange of Hong Kong Limited (“**Stock Exchange**”).

Mr. Wang Yang (“**Mr. Wang**”) has resigned as an independent non-executive Director, chairman of each of the Audit Committee and the Nomination Committee and a member of the Remuneration Committee with effect from 21 October 2022 in order to engage in other business development. Mr. Wang has confirmed that he has no disagreement with the Board and there are no matters relating to his resignation which need to be brought to the attention of the Shareholders or the Stock Exchange.

The Board would like to express its gratitude and appreciation to Mr. Liu and Mr. Wang for their contribution to the Company during their term of office.

By order of the Board
Life Healthcare Group Limited
Yuan Limin
Chief Executive Officer and Executive Director

Hong Kong, 21 October 2022

As at the date of this announcement, the Board comprises:

Executive Directors:

Mr. Yuan Limin (*Chief Executive Officer*)
Mr. Pang Zhen
Mr. Man Wai Lun
Mr. Huang Zhifang

Independent non-executive Directors:

Mr. Chan Man Kiu
Dr. Wang, Bruce Xianliang
Dr. Zhao, Shawn Xiaohong